

- Group V. Claims 24-27, drawn to an animal model for screening therapeutic agents said animal model being characterized by carrying genetic modifications that inactivates its p55 and p75 TNF α receptor protein; classified in Class 800, subclass 8.
- Group VI. Claim 28, drawn to a method for screening a candidate therapeutic agent to determine its efficacy in treating an autoimmune or chronic inflammatory condition that is resistant to treatment with a TNF α inhibitor using an animal model; classified in Class 800, subclass 3.

Claims 1 and 2 link inventions I-IV, the restriction is among the linked inventions.

Applicants elect the claims of **Group I, Claims 1-21**, without traverse, for examination.


The Examiner requires further restriction to a single specific condition such as (a) psoriatic arthritis, (b) arthritis nodosa, (c) seronegative spondylarthropathies, (d) inflammatory bowel diseases, and to list all claims readable thereon.

Applicants elect (a) psoriatic arthritis. Claims 1-2, 4, 6-21 read on the claimed species.

If any issues exist which would hinder allowance of the elected claims, the Examiner is invited to telephone the undersigned representative of the Applicants, to discuss resolution thereof.

Respectfully submitted,


Immunex Corporation
1201 Amgen Court West
Seattle, WA 98119-3105
Telephone: (206) 265-7340
Facsimile: (206) 233-0644


Susan E. Lingenfelter
Registration no. 41,156
Date: October 12, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Oct 12 2005
Date


Kathleen F. Prindle